Successful in vivo gene-therapy trials for OTOF-related deafness have demonstrated that restoring auditory function in humans is achievable, yet there are no current corrective therapeutic options for the treatment of GJB2-related deafness [109,110,111,112]. This evidence concerns the gene GJB2 and deafness.